Abstract
The role of Fas ligand (FasL) in physiologically limiting immune responses and maintaining immune-privileged sites has led to a body of research aiming to confer protection to allogeneic grafts by expressing FasL on the allogeneic tissue or by administrating FasL-transduced donor dendritic cells. In addition, several studies have used FasL to abrogate autoimmune responses. This review presents the results of these studies and discusses the problems associated with FasL usage.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 908-924 |
| Number of pages | 17 |
| Journal | Stem Cells |
| Volume | 22 |
| Issue number | 6 |
| State | Published - 2004 |
Keywords
- Allogeneic
- Dendritic cells
- Fas ligand(FasL)
- gld
- Immune privilege
- lpr
- Tolerance
ASJC Scopus subject areas
- Cell Biology